Bausch Health Expects EPS of 94 Cents in Q2 2025

institutes_icon
LongbridgeAI
07-29 04:54
1 sources

Summary

Bausch Health Companies Inc (BHC.TO) is anticipated to report earnings of $0.94 per share and a 3.4% revenue increase to $2.485 billion for the quarter ending June 30, 2025. The average analyst rating is ‘hold,’ with no strong buy recommendations. The median 12-month price target is $7.00, reflecting a 3.3% increase from the last closing price of $6.77. Previous earnings performance shows mixed results, with some quarters beating estimates and others missing them. Reuters

Impact Analysis

  1. Business Overview Analysis
  • Bausch Health’s core business model involves pharmaceuticals and healthcare products, with revenue primarily from these streams. Their market position indicates stability with a mixed record of meeting earnings expectations. Recent news does not highlight any major strategic shifts or product launches that could significantly alter their competitive stance.
  1. Financial Statement Analysis
  • Income Statement: Expected revenue growth of 3.4% suggests moderate organic growth. The earnings per share (EPS) is anticipated at $0.94.
  • Balance Sheet: No specific changes mentioned, but the focus on revenue and EPS indicates ongoing operations are stable.
  • Cash Flow: Not detailed in the summary. However, consistent earnings imply stable operational cash flows.
  • Key Financial Ratios:
  • Profitability metrics like ROE and ROA can’t be directly calculated without more detailed financial data. But an EPS of $0.94 suggests reasonable profitability.
  • Liquidity, Solvency, and Efficiency metrics would need balance sheet and cash flow data to assess.
  1. Valuation Assessment
  • The price target of $7.00, representing a 3.3% increase from the current price, indicates modest appreciation potential. The absence of strong buy recommendations implies cautious investor sentiment.

The analysis suggests Bausch Health is experiencing stable but unspectacular financial performance, with no significant positive or negative catalysts highlighted in the report. Reuters

Event Track